The expression of MDR1 was found to be low in ovarian carcinomas when BRCA1-deficient mammary tumors were diagnosed initially, whereas the upregulation of this pump protein always occured in parallel with acquired resistance to chemotherapy, including PARPi [132, 136]. This evidence concerns the gene ABCB1 and ovarian carcinoma.